Literature DB >> 26756631

Pathophysiology of Heart Failure.

Edit Tanai1,2, Stefan Frantz2,3.   

Abstract

Heart failure is considered an epidemic disease in the modern world affecting approximately 1% to 2% of adult population. It presents a multifactorial, systemic disease, in which--after cardiac injury--structural, neurohumoral, cellular, and molecular mechanisms are activated and act as a network to maintain physiological functioning. These coordinated, complex processes lead to excessive volume overload, increased sympathetic activity, circulation redistribution, and result in different, parallel developing clinical signs and symptoms. These signs and symptoms sum up to an unspecific clinical picture; thus invasive and noninvasive diagnostic tools are used to get an accurate diagnosis and to specify the underlying cause. The most important, outcome determining factor in heart failure is its constant progression. Constant optimizing of pharmatherapeutical regimes, novel targets, and fine regulation of these processes try to keep these compensatory mechanisms in a physiological range. Beside pharmacological therapy, interventional and surgical therapy options give new chances in the management of heart failure. For the optimization and establishment of these and novel therapeutical approaches, complete and comprehensive understanding of the underlying mechanisms is essentially needed. Besides diagnosis and treatment, efforts should be made for better prevention in heart failure by treatment of risk factors, or identifying and following risk groups. This summary of the pathophysiology of heart failure tries to give a compact overview of basic mechanisms and of the novel unfolding, progressive theory of heart failure to contribute to a more comprehensive knowledge of the disease.
Copyright © 2015 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26756631     DOI: 10.1002/cphy.c140055

Source DB:  PubMed          Journal:  Compr Physiol        ISSN: 2040-4603            Impact factor:   9.090


  101 in total

Review 1.  Centrally Mediated Cardiovascular Actions of the Angiotensin II Type 2 Receptor.

Authors:  U Muscha Steckelings; Annette de Kloet; Colin Sumners
Journal:  Trends Endocrinol Metab       Date:  2017-07-18       Impact factor: 12.015

2.  AMPK-mediated cardioprotection of atorvastatin relates to the reduction of apoptosis and activation of autophagy in infarcted rat hearts.

Authors:  Qing Li; Qiu-Ting Dong; Yue-Jin Yang; Xia-Qiu Tian; Chen Jin; Pei-Sen Huang; Lei-Pei Jiang; Gui-Hao Chen
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

3.  Laparoscopic Bypass in Morbidly Obese Patient with End-Stage Heart Failure: Case Report.

Authors:  Christian Lamar Scheibe; Luis Eduardo Veras Pinto; José Aparecido Valadão; Caio Márcio Barros de Oliveira; Ed Carlos Rey Moura; Giuliano Peixoto Campelo; Roclides Castro de Lima; Thyago Trisotto Freire; Eduardo José Silva Gomes de Oliveira; Plínio da Cunha Leal
Journal:  Obes Surg       Date:  2021-07-02       Impact factor: 4.129

Review 4.  Pulmonary Artery Denervation: Update on Clinical Studies.

Authors:  Hang Zhang; Shao-Liang Chen
Journal:  Curr Cardiol Rep       Date:  2019-09-05       Impact factor: 2.931

5.  Common pathways and communication between the brain and heart: connecting post-traumatic stress disorder and heart failure.

Authors:  Marlene A Wilson; Israel Liberzon; Merry L Lindsey; Yana Lokshina; Victoria B Risbrough; Renu Sah; Susan K Wood; John B Williamson; Francis G Spinale
Journal:  Stress       Date:  2019-06-04       Impact factor: 3.493

Review 6.  Modeling heart failure in animal models for novel drug discovery and development.

Authors:  Paul M L Janssen; Mohammad T Elnakish
Journal:  Expert Opin Drug Discov       Date:  2019-03-12       Impact factor: 6.098

Review 7.  G-Protein-Coupled Receptors in Heart Disease.

Authors:  Jialu Wang; Clarice Gareri; Howard A Rockman
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

Review 8.  Irisin: linking metabolism with heart failure.

Authors:  Jiamin Li; Susu Xie; Lei Guo; Jun Jiang; Han Chen
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

9.  MiR-221-3p targets Hif-1α to inhibit angiogenesis in heart failure.

Authors:  Yuying Li; Chenghui Yan; Jiahui Fan; Zhiwei Hou; Yaling Han
Journal:  Lab Invest       Date:  2020-09-01       Impact factor: 5.662

10.  Cardiovascular response to small-molecule APJ activation.

Authors:  Brandon Ason; Yinhong Chen; Qi Guo; Kimberly M Hoagland; Ray W Chui; Mark Fielden; Weston Sutherland; Rhonda Chen; Ying Zhang; Shirley Mihardja; Xiaochuan Ma; Xun Li; Yaping Sun; Dongming Liu; Khanh Nguyen; Jinghong Wang; Ning Li; Sridharan Rajamani; Yusheng Qu; BaoXi Gao; Andrea Boden; Vishnu Chintalgattu; Jim R Turk; Joyce Chan; Liaoyuan A Hu; Paul Dransfield; Jonathan Houze; Jingman Wong; Ji Ma; Vatee Pattaropong; Murielle M Véniant; Hugo M Vargas; Gayathri Swaminath; Aarif Y Khakoo
Journal:  JCI Insight       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.